11 articles
Roche announced plans to build autonomous AI labs to accelerate drug discovery, aiming to reallocate $2 billion in R&D savings by 2026. The company targets 20 new molecular entities by 2030 with AI dr
Roche has nominated Christoph Weber, former CEO of Takeda Pharmaceuticals, for election to its board of directors at the upcoming Annual General Meeting in March. Company leadership cites his extensiv
Anthropic established a physical biology lab to advance AI-driven drug discovery, partnering with major pharma firms like Novartis and Roche. The company acquired Coefficient Bio to accelerate develop
Swiss GDP grew 1.5% in Q2, surpassing forecasts and driven by pharmaceuticals and chemicals. Pharma giants Novartis and Roche posted earnings beats, reinforcing the sector's contribution to national e
The U.S. may launch a Section 301 trade investigation into Switzerland's pharmaceutical sector over potential price cuts, mirroring actions against Germany. Industry leaders warn this could impact maj
Roche and Novartis warn a proposed Swiss population cap threatens skilled talent access, risking R&D capabilities in Basel. Industry leaders argue this undermines Switzerland's status as a global phar
Eli Lilly solidified its obesity drug market leadership after presenting superior trial data at the American Diabetes Association meeting. Competitors like Roche and Pfizer unveiled new candidates, th
Swiss companies invested $27 billion in the U.S. between January and April following a tariff agreement reducing duties on Swiss goods. Major pharmaceutical firms Novartis and Roche announced new faci
Roche Chairman Severin Schwan criticized U.S. tariff policies on drugmakers as "blackmail" following an agreement to slash medicine prices under threat of steep tariffs. He identified U.S. and Chinese
Swiss pharmaceutical giant Roche agreed to acquire U.S.-based PathAI for $750 million upfront plus up to $300 million in milestone payments. The deal aims to strengthen Roche's position in AI-driven d
Roche reported a 5% Q1 sales decline due to foreign exchange impacts, though constant-rate sales grew 6% driven by its pharmaceuticals division while maintaining full-year growth targets.
ChemBrief